Latest News

Vectura Wins US GSK Patent Litigation and Awarded $89.7Million in Damages by Trial Jury



CHIPPENHAM, United Kingdom–(BUSINESS WIRE)–Vectura Group plc (LSE:VEC) ("Vectura" or "the Group") confirms that on 3rd May 2019 following a jury trial in the United States District Court for the District of Delaware, the relevant asserted claim of Vectura’s US patent 8303991 was found valid and infringed by US sales of three of GlaxoSmithKline’s (GSK) Ellipta products. The jury awarded Vectura $89.7m in damages for the period from August 2016 through December 2018, based on a calculation of 3

Source link

Related posts

Weight before pregnancy most important to risk for complications

Newsemia

Study highlights role of doctor conflicts of interest in Medicare spending on Mallinckrodt drug Acthar

Newsemia

New Swine Flu Is Making Headlines: Why You Shouldn’t Worry

Newsemia

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy

COVID-19

COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World